Modulation of the Complement System by Human Beta-defensin 2

Overview

Journal J Burns Wounds

Date 2007 Jan 20

PMID 17235375

Citations 12

Authors

Satyanarayan Bhat

Yau-Hau Song

Carl Lawyer

Stephen M Milner

Affiliations

Soon will be listed here.

Abstract

Objective: Human beta-defensin (HBD) and the complement system are two important innate immune mechanisms active against a broad range of burn and wound pathogens. However, excessive or uncontrolled complement activation, following thermal injury, contributes to tissue damage. Previous studies from our laboratory suggested a decreased expression of HBD-2 in burn wounds and its absence in burn blister fluid. Prior studies have demonstrated that human neutrophil peptide can bind to the C1q component of the complement system and prevent complement activation. The objective of this study was to determine whether HBD-1 and HBD-2 can also bind to the C1q component and modulate complement activity.

Methods: The binding efficiency of HBD-1 and HBD-2 to the C1q component was determined by utilizing dot blot hybridization. The effect of HBD-2 on the activation of the complement system by the classical and alternative pathways was determined by CH50 and AP50 assays. In addition, the ability of HBD-1 and HBD-2 to inhibit C1q activity was predicted by a comparison with known C1q inhibitor peptide 2J in a DNAStar computer modeling study.

Results: C1q binding to HBD-2 was strong, whereas C1q binding to HBD-1 was weak. HBD-2 inhibits the classical pathway significantly without affecting the alternative pathway. In addition, a computer modeling study also revealed structural homology of HBD-2 with known C1q inhibitory sequences of HBD-2.

Conclusion: HBD-2 inhibits the classical pathway. The replacement of missing defensin, a natural inhibitor of the complement system, may have a dual protective role not only as an antimicrobial agent but also in providing protection against uncontrolled activation of the complement system.

Citing Articles

Characterization of Angiogenic, Matrix Remodeling, and Antimicrobial Factors in Preterm and Full-Term Human Umbilical Cords.

Zarina K, Pilmane M J Dev Biol. 2024; 12(2).

PMID: 38804433 PMC: 11130933. DOI: 10.3390/jdb12020013.

Role of Defensins in Tumor Biology.

Adyns L, Proost P, Struyf S Int J Mol Sci. 2023; 24(6).

PMID: 36982340 PMC: 10049535. DOI: 10.3390/ijms24065268.

Human β-Defensin 2 and Its Postulated Role in Modulation of the Immune Response.

Cieslik M, Baginska N, Gorski A, Jonczyk-Matysiak E Cells. 2021; 10(11).

PMID: 34831214 PMC: 8616480. DOI: 10.3390/cells10112991.

The Addition of a Synthetic LPS-Targeting Domain Improves Serum Stability While Maintaining Antimicrobial, Antibiofilm, and Cell Stimulating Properties of an Antimicrobial Peptide.

Maystrenko A, Feng Y, Akhtar N, Li J Biomolecules. 2020; 10(7).

PMID: 32650576 PMC: 7407491. DOI: 10.3390/biom10071014.

Expression and Function of Host Defense Peptides at Inflammation Sites.

Prasad S, Fiedoruk K, Daniluk T, Piktel E, Bucki R Int J Mol Sci. 2019; 21(1).

PMID: 31877866 PMC: 6982121. DOI: 10.3390/ijms21010104.

References

Church D, Elsayed S, Reid O, Winston B, Lindsay R . Burn wound infections. Clin Microbiol Rev. 2006; 19(2):403-34. PMC: 1471990. DOI: 10.1128/CMR.19.2.403-434.2006. View

Panyutich A, Szold O, Poon P, Tseng Y, Ganz T . Identification of defensin binding to C1 complement. FEBS Lett. 1994; 356(2-3):169-73. DOI: 10.1016/0014-5793(94)01261-x. View

Scholz W, McClurg M, Cardenas G, Smith M, Noonan D, Hugli T . C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol. 1990; 57(2):297-307. DOI: 10.1016/0090-1229(90)90043-p. View

Garcia J, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U . Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res. 2001; 306(2):257-64. DOI: 10.1007/s004410100433. View

Roos A, Nauta A, Broers D, Trouw L, Drijfhout J, Daha M . Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol. 2001; 167(12):7052-9. DOI: 10.4049/jimmunol.167.12.7052. View

Yamashita T, Saito K . Purification, primary structure, and biological activity of guinea pig neutrophil cationic peptides. Infect Immun. 1989; 57(8):2405-9. PMC: 313461. DOI: 10.1128/iai.57.8.2405-2409.1989. View

Ghebrehiwet B, Kew R, Gruber B, Marchese M, Peerschke E, Reid K . Murine mast cells express two types of C1q receptors that are involved in the induction of chemotaxis and chemokinesis. J Immunol. 1995; 155(5):2614-9. View

Ziccardi R, Cooper N . Active disassembly of the first complement component, C-1, by C-1 inactivator. J Immunol. 1979; 123(2):788-92. View

Cavaillon J, Fitting C, Haeffner-Cavaillon N . Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol. 1990; 20(2):253-7. DOI: 10.1002/eji.1830200204. View

10.

Zanotti S, Kumar A, Kumar A . Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs. 2002; 11(8):1061-75. DOI: 10.1517/13543784.11.8.1061. View

11.

Bjork J, Hugli T, Smedegard G . Microvascular effects of anaphylatoxins C3a and C5a. J Immunol. 1985; 134(2):1115-9. View

12.

Lauvrak V, Brekke O, Ihle O, Lindqvist B . Identification and characterisation of C1q-binding phage displayed peptides. Biol Chem. 1998; 378(12):1509-19. DOI: 10.1515/bchm.1997.378.12.1509. View

13.

Chertov O, Michiel D, Xu L, Wang J, Tani K, Murphy W . Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem. 1996; 271(6):2935-40. DOI: 10.1074/jbc.271.6.2935. View

14.

Sparkes B . Immunological responses to thermal injury. Burns. 1997; 23(2):106-13. DOI: 10.1016/s0305-4179(96)00089-7. View

15.

Territo M, Ganz T, Selsted M, LEHRER R . Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest. 1989; 84(6):2017-20. PMC: 304087. DOI: 10.1172/JCI114394. View

16.

Nepomuceno R, Burgess W, Tenner A . cDNA cloning and primary structure analysis of C1qR(P), the human C1q/MBL/SPA receptor that mediates enhanced phagocytosis in vitro. Immunity. 1997; 6(2):119-29. DOI: 10.1016/s1074-7613(00)80419-7. View

17.

Milner S, Bhat S, Buja M, Gulati S, Poindexter B, Bick R . Expression of human beta defensin 2 in thermal injury. Burns. 2004; 30(7):649-54. DOI: 10.1016/j.burns.2004.06.001. View

18.

ORTEGA M, Ganz T, Milner S . Human beta defensin is absent in burn blister fluid. Burns. 2000; 26(8):724-6. DOI: 10.1016/s0305-4179(00)00052-8. View

19.

Fiane A, Mollnes T, Videm V, Hovig T, Hogasen K, Mellbye O . Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 1999; 6(1):52-65. DOI: 10.1034/j.1399-3089.1999.00007.x. View

20.

Poindexter B, Bhat S, Buja L, Bick R, Milner S . Localization of antimicrobial peptides in normal and burned skin. Burns. 2006; 32(4):402-7. DOI: 10.1016/j.burns.2006.01.021. View